Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment
نویسندگان
چکیده
منابع مشابه
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
BACKGROUND The common -514 C-->T polymorphism in the promoter region of the hepatic lipase (HL) gene affects HL activity. The C allele is associated with higher HL activity, more dense and atherogenic LDL, and lower HDL(2) cholesterol. Intensive lipid-lowering therapy lowers HL activity, increases LDL and HDL buoyancy, and promotes coronary artery disease (CAD) regression. We tested the hypothe...
متن کاملPromoter Variants and Variant Promoters of the Hepatic Lipase Gene
Het onderzoek beschreven in dit proefschrift werd uitgevoerd op de afdeling Biochemie Cardiovascular Research School COEUR en de afdeling interne geneeskunde van de Erasmus Universiteit te Rotterdam. 1.0 Introduction 7 1.1 Role of Hepatic lipase in lipoprotein metabolism 8 1.1.1 Hepatic lipase 8 1.1.2 Hepatic lipase and reverse cholesterol transport 10 1.1.3 Hepatic lipase and steroidogenesis 1...
متن کاملTranscriptional regulation of the human hepatic lipase (LIPC) gene promoter.
Hepatic lipase (HL) plays a key role in the metabolism of plasma lipoproteins, and its level of activity requires tight regulation, given the association of both low and high levels with atherosclerosis and coronary artery disease. However, little is known about the factors responsible for HL expression. Here, we report that the human hepatic lipase gene (LIPC) promoter is regulated by hepatocy...
متن کاملCommon variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol.
Increased hepatic lipase (HL) activity is associated with small, dense, low density lipoprotein (LDL) and low high density lipoprotein2 (HDL2) cholesterol (-C) levels. A polymorphism in the promoter region of the HL gene (LIPC) is associated with HDL-C levels. To test whether this association is mediated by differences in HL activity between different LIPC promoter genotypes, the LIPC promoter ...
متن کاملHeterogeneity of response to lipid-lowering therapy.
the follow-up (from 3 to 2 and 0), simply after evaluating them, performing the tilt table test and explaining the pathogenesis of the disease. This fact may explain Dr. Sra’s (2) skepticism on the medical capacity to prove the benefit of any treatment for vasovagal syncope. This could also be the reason why almost any treatment that has been tested for the therapy of vasovagal syncope has been...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2001
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.103.6.792